Liver Abscess After Transarterial Chemoembolization in Patients With Bilioenteric Anastomosis: Frequency and Risk Factors

Size: px
Start display at page:

Download "Liver Abscess After Transarterial Chemoembolization in Patients With Bilioenteric Anastomosis: Frequency and Risk Factors"

Transcription

1 Vascular and Interventional Radiology Original Research Woo et al. Liver Abscess After Transarterial Chemoembolization Vascular and Interventional Radiology Original Research Sungmin Woo 1 Jin Wook Chung Saebeom Hur Seung-Moon Joo Hyo-Cheol Kim Hwan Jun Jae Jae Hyung Park Woo S, Chung JW, Hur S, et al. Keywords: bilioenteric anastomosis, liver abscess, risk factor, technique, transarterial chemoembolization DOI: /AJR Received July 16, 2012; accepted after revision August 24, All authors: Department of Radiology, Seoul National University College of Medicine, 101 Daehak-ro, Jongnogu, Seoul , Korea. Address correspondence to J. W. Chung (chungjw@snu.ac.kr). AJR 2013; 200: X/13/ American Roentgen Ray Society Liver Abscess After Transarterial Chemoembolization in Patients With Bilioenteric Anastomosis: Frequency and Risk Factors OBJECTIVE. The purpose of this study was to clarify the frequency of and risk factors for liver abscess formation after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma or metastatic hepatic tumors after undergoing bilioenteric anastomosis. MATERIALS AND METHODS. From January 1996 to June 2012, 25 patients (21 men, four women; age range, years) with hepatocellular carcinoma (n = 12) or metastatic hepatic tumors (n = 13) with an underlying bilioenteric anastomosis underwent 65 TACE procedures. The incidence of liver abscess, predisposing factors (diabetes, Child-Pugh class, leukopenia, tumor number, tumor size, tumor burden, tumor type, portal vein thrombus, lipiodol dose, particulate embolization, embolization selectivity, oily portogram, antibiotic prophylaxis, and occurrence of liver abscess at initial TACE), and clinical outcome were evaluated. Statistical analysis for relations between liver abscess and predisposing factors was performed by Fisher exact test and linear-by-linear association. RESULTS. Liver abscess developed after 17 of 65 (26.2%) TACE procedures performed on 12 of 25 (48%) patients. Two patients died of progression of liver abscess into sepsis. Univariate and multivariate analyses showed that leukopenia (p = 0.029), occurrence of liver abscess at initial TACE (p = 0.082), and particulate embolization or oily portogram (grade 2) (p = 0.001) were associated with a higher incidence of liver abscess. CONCLUSION. The incidence of liver abscess was high among patients with bilioenteric anastomoses who underwent TACE. Leukopenia, occurrence of liver abscess at initial session of TACE, and particulate embolization or oily portogram (grade 2) were associated with the development of liver abscess. T ransarterial chemoembolization (TACE) has become a popular treatment of unresectable hepatocellular carcinoma (HCC) and meta static hepatic tumors [1 4]. It is associated with a variety of hepatic and biliary damage, including hepatic failure, liver abscess, and biloma formation [5]. Although the reported incidence of liver abscess formation is low ( %) [6 9], bilioenteric anastomosis significantly increases risk [7]. An odds ratio up to 894 was reported by Kim et al. [8]. Moreover, high mortality rates, ranging from 13.3% to 50% have been reported after an abscess has complicated TACE [7, 10, 11]. Therefore, avoidance of TACE in the care of these patients has been recommended, but if TACE is performed, broad-spectrum antibiotics and bowel preparation should be administered [12]. There has been controversy, however, over the role of antibiotics in preventing abscess formation after TACE [8, 13 15]. Furthermore, no consensus has been reached with regard to patient selection. To the best of our knowledge, no study has been focused on risk factors, especially those concerning the technical methods of TACE procedures, for the development of liver abscess after TACE in patients with a history of bilioenteric anastomosis. We believe that limiting the study population to only patients with a history of bilioenteric anastomosis would facilitate identification of risk factors and would contribute to improving the safety of chemoembolization. The purpose of this study was to clarify the frequency of and risk factors for liver abscess formation after TACE in patients with HCC or metastatic hepatic tumors who previously underwent bilioenteric anastomosis. Materials and Methods Study Population This retrospective study was approved by our institutional review board. Informed consent was 1370 AJR:200, June 2013

2 Liver Abscess After Transarterial Chemoembolization A C E Fig year-old man with hepatocellular carcinoma who had undergone pylorus-preserving pancreaticoduodenectomy because of distal common bile duct cancer 3 years earlier. A, Gadoxetic acid enhanced MR image shows 3.2-cm mass with hepatobiliary phase defect in liver segment VII that proved to be hepatocellular carcinoma at ultrasound-guided percutaneous liver biopsy (not shown). B, Celiac angiogram shows mass with hypervascular tumor staining. C, Transarterial chemoembolization (TACE) was performed with subsegmental level of catheter tip placement (not shown). Fluoroscopic image obtained during TACE shows grade 2 oily portogram. Additional particulate embolization was performed until complete arterial flow stasis was achieved. D, CT image obtained 12 days after TACE shows large liver abscess adjacent to mass compacted with iodized oil. E, Fluoroscopic image shows appearance at percutaneous catheter drainage with 10.5-French catheter performed 13 days after TACE. F, CT image obtained 2 months after TACE shows liver abscess has resolved. Air is present in both intrahepatic ducts because of underlying pylorus-preserving pancreaticoduodenectomy. B D F AJR:200, June

3 Woo et al. waived for this records-based study. A computerized search was performed of medical records from January 1996 to June 2012 for patients with a history of bilioenteric anastomosis who underwent TACE procedures at our institution. A total of 87 TACE procedures were performed for hepatic tumors in 35 patients. Six patients who underwent 18 TACE procedures were excluded because TACE was performed before bilioenteric anastomosis. Another four patients who underwent four procedures were excluded from analysis because embolization was performed for bleeding control (three patients) or as empirical embolization without definite evidence of tumor at CT or angiography (one patient). Ultimately, a total of 25 patients (21 men, four women; mean age, 57.8 ± 12.5 [SD] years; range, years) who underwent 65 TACE procedures were included in our study. The types of bilioenteric anastomosis were Whipple operation (eight patients), pylorus-preserving pancreaticoduodenectomy (nine patients), and liver resection involving or choledochojejunostomy (eight patients). The diagnoses of 12 HCCs and 13 metastatic hepatic tumors were made as follows: Four HCCs and six metastatic hepatic tumors were diagnosed with percutaneous biopsy. The other HCCs were diagnosed clinically on the basis of risk factors and radiologic features of the tumor on dynamic contrast-enhanced CT scans or dynamic MR images according to the clinical guidelines proposed by the American Association for the Study of Liver Diseases [16] in eight patients. For the other seven patients with metastatic tumors, diagnosis was based on a recent history of surgery- or biopsy-proven extrahepatic primary malignancy, elevated concentrations of tumor markers, and consistent imaging findings. The metastatic hepatic tumors were six pancreatic neuroendocrine tumors, two duodenal gastrointestinal stromal tumors, two duodenal leiomyosarcomas, two adenocarcinomas of the ampulla of Vater, and one gastric neuroendocrine tumor. Methods of Chemoembolization and Follow-Up Informed consent was obtained from all patients before each TACE procedure. First, 2 15 ml (mean, 5.6 ± 3.1 ml) of iodized oil (Lipiodol, Andre Guerbet) and mg of doxorubicin hydrochloride (ADM, Dong-a) emulsion was intraarterially infused. In preparation of an iodized oil anticancer drug emulsion, 10 mg of doxorubicin hydrochloride was dissolved in 0.5 ml of water-soluble contrast medium (iopamidol, Iopamiro 300, Bracco). Iodized oil and dissolved doxorubicin hydrochloride were then mixed by a pumping technique that entailed two syringes connected by a three-way stopcock [7]. Depending on the operator s discretion, particulate embolization was performed with absorbable gelatin sponge particles (1 2 mm in diameter; Gelfoam, Upjohn) soaked in 20 ml of iopromide (Ultravist 370, Bayer Schering Pharma). Further TACE sessions were planned individually according to tumor response and the patient s tolerance of the procedure. For example, when follow-up evaluation with CT and alpha-fetoprotein measurement showed liver function was severely deteriorated or tumor had undergone complete remission, additional TACE was not performed. After each procedure, we periodically assessed patients for treatment-related complications. When liver abscess was suspected, the patient underwent contrast-enhanced CT of the liver. Otherwise, iodized oil CT or contrast-enhanced CT was performed routinely 2 3 weeks after the procedure. Investigation of Liver Abscess The medical records of all 25 patients were retrospectively reviewed for the development of liver abscess after each TACE session. Liver abscess was defined as a hypoattenuating lesion with peripheral rim enhancement on CT images if the patient met any of the three following conditions: blood or aspirate culture revealed bacteria; aspirate from percutaneous drainage had a purulent appearance; or temperature higher than 38.5 C lasted more than 5 days with leukocyte count greater than /L without another cause [17]. Investigation of Predisposing Factors We defined several variables regarding patient and tumor characteristics and methods of TACE as risk factors for the development of liver abscess after TACE. They were diabetes mellitus, Child- Pugh class, leukopenia, tumor number, maximum tumor size, tumor burden, tumor type (HCC vs metastasis), portal vein thrombus for patient and tumor characteristics and lipiodol dose, particulate embolization, degree of embolization selectivity, achievement of oily portogram, and antibiotic prophylaxis for methods of TACE. In addition, whether a liver abscess occurred at initial TACE was evaluated for the repeated sessions of TACE. An interventional radiologist with 20 years experience and a radiologist with 2 years experience retrospectively reviewed the medical records and radiographs of the TACE procedures for predisposing factors. Leukopenia was defined as a WBC count less than 4000/µL. Particulate embolization was graded as follows: 0, no embolic material used; 1, embolic materials used without achievement of arterial stasis; 2, embolic materials used with achievement of arterial stasis. Visualization of an oily portogram was categorized according to the classification suggested by Miyayama et al. [18]: grade 0, no obvious visualization; 1, slight visualization; 2, marked visualization. Degree of embolization selectivity was categorized as follows according to the location of the catheter tip on embolization: lobar or sectional, segmental, and subsegmental. Statistical Analysis Statistical analysis was performed with software (SPSS version 17.0, SPSS). Fisher exact test or linear-by-linear association was used to evaluate the relation between the risk factors and liver abscess. Variables with p < 0.1 were taken into consideration for multivariate linear logistic regression analysis. Finally, p < 0.05 at multivariate analysis was considered to indicate a significant difference. Results Frequency of Predisposing Factors Among the patients who underwent TACE, 12 patients with HCC underwent 33 TACE procedures. The other 13 patients with metastatic hepatic tumor underwent 32 TACE procedures. Seven (28%) patients had diabetes mellitus. The Child-Pugh class was A in 58 (89.2%) and B in seven (10.8%) procedures. WBC count ranged from 2220 to 11,900/µL (mean, 5830 ± 2280/ µl), and leukopenia was observed before 13 (20%) procedures. A single tumor was treated in 26 (40%) sessions, two tumors in nine (13.8%) sessions, three tumors in three (4.6%) sessions, and four or more tumors in 27 (41.5%) sessions. Maximum tumor size ranged from 0.1 to 12.1 cm (mean, 2.5 ± 2.1 cm) in greatest diameter. Tumor burden was less than 10% in 57 (87.7%) cases and 10% or more in eight (12.3%) cases. Portal vein thrombosis was found in three (4.6%) procedures at the right secondorder branch. The dose of iodized oil ranged from 2 to 15 ml (mean, 5.6 ± 3.1 ml). Particulate embolization was performed with grades 1 and 2 in 14 (21.5%) and 20 (30.8%) procedures. Oily portogram after TACE was obtained with grades 1 and 2 in six (9.2%) and 14 (21.5%) procedures. The selective degree of embolization was lobar or sectional in 28 (43.1%), segmental in 19 (29.2%), and subsegmental in 18 (27.7%) sessions. Antibiotic prophylaxis was administered before TACE in 17 (26.2%) sessions. Incidence of Liver Abscess Liver abscess developed after 17 of 65 (26.2%) TACE procedures performed on 12 of 25 (48%) patients (Fig. 1). The clinical profiles and methods of TACE for these 12 patients are summarized in Table 1. In 7 of 25 (28%) patients liver abscess developed after the first session of TACE. These seven patients underwent seven additional TACE procedures and had four (57.1%) liver abscesses. The other 18 of 25 (72%) patients without liver abscess after the initial TACE procedure 1372 AJR:200, June 2013

4 Liver Abscess After Transarterial Chemoembolization TABLE 1: Characteristics of Patients With Liver Abscess After Transarterial Chemoembolization (TACE) Patient. No. Age (y) Sex Diagnosis Child-Pugh Class Diabetes Mellitus WBC Count (/µl) Bilioenteric Anastomosis Type Tumor Size (cm) No. of Tumors No. of Sessions a Particulate Embolization Grade Oily Portogram Grade TACE Selectivity Iodized Oil Dose (ml) Doxorubicin Dose (mg) Antibiotics 1, procedure 1 68 M HCC A Yes 11,330 Central bisegmentectomy, choledochojejunostomy Segmental 3 20 Yes 1, procedure 2 68 M HCC A Yes 10,700 Central bisegmentectomy, choledochojejunostomy Segmental 3 20 No 2 80 M HCC A No 3810 Whipple operation Subsegmental 6 30 No 3, procedure 1 43 M Pancreatic neuroendocrine tumor A No 6000 Whipple operation Subsegmental 3 20 No 3, procedure 2 43 M Pancreatic neuroendocrine tumor A No 4910 Whipple operation Subsegmental 4 30 No 4 72 M Duodenal GIST A No 3220 Whipple operation Lobar No 5 56 F Pancreatic neuroendocrine tumor B Yes 3800 Whipple operation Segmental Yes 6, procedure 1 73 M HCC A Yes 5700 PPPD Subsegmental 4 30 No 6, procedure 2 74 M HCC A Yes 6400 PPPD Subsegmental 6 30 Yes 7 61 F Adenocarcinoma of ampulla of Vater A No 6000 PPPD Segmental 8 50 No 8 71 M Pancreatic neuroendocrine tumor A No 6700 PPPD Subsegmental 6 30 No 9 66 M HCC A No 4700 PPPD Subsegmental 4 20 Yes M HCC A Yes 11,900 Right lobectomy Subsegmental 2 10 No M HCC A No 4085 Left lobectomy Segmental 4 30 No 12, procedure 1 51 M HCC B No 3150 Right lobectomy Lobar 7 40 No 12, procedure 2 51 M HCC B No 3840 Right lobectomy Lobar 5 30 Yes 12, procedure 3 51 M HCC B No 2990 Right lobectomy Segmental 2 10 Yes Note HCC = hepatocellular carcinoma, GIST = gastrointestinal stromal tumor, PPPD = pylorus-preserving pancreaticoduodenectomy. a Total number of TACE sessions before liver abscess formation. AJR:200, June

5 Woo et al. TABLE 2: Relation Between All Variables and Abscess Formation in 25 Initial Transarterial Chemoembolization Procedures for Hepatocellular Carcinoma and Metastatic Hepatic Tumors in 25 Patients Liver Abscess Formation Variable Without Predisposing Factor underwent 33 additional TACE procedures and had six (18.2%) liver abscesses. Cultures of blood or aspirate revealed bacteria in 14 of 17 (82.4%) cases. Blood culture results were positive in nine cases (52.9%). The causative organisms were Klebsiella pneumoniae in four cases, Bacteroides fragilis in one case, Escherichia coli in four cases, and Enterococcus faecium in four cases. Results of aspirate cultures were positive in seven cases (41.2%). The causative organisms were K. pneumoniae in two cases, E. coli in three cases, E. faecium in one case, and Pseudomonas aeruginosa in one case. With Predisposing Factor Child-Pugh class B 6/22 (27.3) 1/3 (33.3) Diabetes mellitus 4/18 (22.2) 3/7 (42.9) Leukopenia 6/21 (28.6) 1/4 (25.0) Antibiotics 2/7 (28.6) 5/18 (27.8) Single tumor 4/16 (25.0) 3/9 (33.3) Tumor size 3 cm 5/18 (27.8) 2/7 (28.6) Tumor burden 10% 6/20 (30.0) 1/5 (20.0) Type of tumor (hepatocellular carcinoma) 2/13 (15.4) 5/12 (41.7) Portal vein thrombosis 7/24 (29.2) 0/1 (0.0) Iodized oil dose a Embolization (grade 2) 1/15 (6.7) 6/10 (60.0) Oily portogram (grade 2) 2/18 (11.1) 5/7 (71.4) Selectivity a Embolization or portogram (grade 2) 1/15 (6.7) 6/10 (60.0) Note Numbers in parentheses are percentages. Linear-by-linear association. TABLE 3: Relation Between All Variables and Abscess Formation in 40 Repeated Transarterial Chemoembolization (TACE) Procedures for Hepatocellular Carcinomas and Metastatic Hepatic Tumors in 15 Patients Variable Liver Abscess Formation With Predisposing Factor No Yes p (Univariate) a p (Multivariate) b Odds Ratio 90% CI for Odds Ratio Child-Pugh class B 7/36 (19.4) 3/4 (75.0) Diabetes mellitus 7/24 (29.2) 3/16 (18.8) Leukopenia 5/31 (16.1) 5/9 (55.6) Antibiotics 4/10 (40.0) 6/30 (20.0) Single tumor 4/23 (17.4) 6/17 (35.3) Tumor size 3 cm 7/29 (24.1) 3/11 (27.3) Tumor burden 10% 9/37 (24.3) 1/3 (33.3) Type of tumor (HCC) 4/19 (21.1) 6/21 (28.6) Portal vein thrombosis 10/38 (26.3) 0/2 (0.0) Iodized oil dose c Embolization or portogram (grade 2) 2/21 (9.5) 8/19 (42.1) Abscess at first TACE 6/33 (18.2) 4/7 (57.1) Note Numbers in parentheses are percentages. a p for Fisher exact test analyzed for all variables. b p for multivariate linear logistic regression analysis analyzed for variables with p < 0.1 in univariate analysis. c Linear-by-linear association. Relation Between Liver Abscess Formation and Predisposing Factors The incidences of liver abscess for each potential risk factor compared with the corresponding control group are shown in Tables 2 4. Of the 25 initial TACE procedures, grade 2 embolization (6/10, p = 0.007), grade 2 p 1374 AJR:200, June 2013

6 Liver Abscess After Transarterial Chemoembolization TABLE 4: Relation Between All Variables and Abscess Formation in All 65 Transarterial Chemoembolization Procedures for Hepatocellular Carcinoma and Metastatic Hepatic Tumors in 25 Patients Liver Abscess Formation With Predisposing Factor Variable oily portogram visualization (5/7, p = 0.007), and higher selectivity of TACE (p = 0.051) correlated with higher incidence of liver abscess formation (Table 2). With regard to the TACE technique at our institution, where we tend to perform higher degrees of particulate embolization (p = 0.001) and to achieve higher grades of oily portogram visualization (p = 0.002) with higher selectivity, we integrated the three variables into a single factor: grade 2 embolization or oily portogram. This integrated factor significantly correlated with liver abscess formation (6/10, p = 0.007). Of the 40 repeated sessions of TACE, the following were associated with higher incidence of liver abscess (Table 3): Child-Pugh class B (3/4, p = 0.042), leukopenia (5/9, p = 0.029), grade 2 embolization or oily portogram (8/19, p = 0.028), and abscess at initial TACE (4/7, p = 0.052). In multivariate linear regression analysis (Child-Pugh class was excluded because all four patients with Child-Pugh class B had leukopenia), leukopenia (p = 0.033) and embolization or oily portogram (grade 2) (p = 0.020) were statistically significant. Experience of abscess at initial TACE had borderline association (p = 0.082; 90% CI, ) Of the total of 65 TACE procedures, Child- Pugh class B (4/7, p = 0.070), leukopenia (6/13, p = 0.085), and grade 2 embolization or oily portogram (14/29, p < 0.001) were associated with liver abscess development (Table 4). In multivariate linear regression analysis (Child-Pugh class was excluded because all No Yes four patients with Child-Pugh class B disease in whom a liver abscess developed had leukopenia), leukopenia (6/13, p = 0.029) and grade 2 embolization or oily portogram (14/29, p = 0.001) were statistically significant. Treatment and Clinical Outcome All patients underwent treatment with parenteral antibiotics. Percutaneous catheter drainage (PCD) with to 14-French catheters was performed in nine patients (10 sessions), who recovered. The other seven patients (seven sessions) did not undergo PCD insertion owing to lack of safe access (patient 1), death before PCD could be performed (patient 3), and surgeon s specific request for diagnostic aspiration only (patient 9). The reason for not performing PCD could not be identified from the medical records of the other four patients. Of the seven patients who did not undergo PCD, five patients recovered without further event. However, two patients (patients 1 and 3) died of progression of liver abscess to sepsis 23 days after and on the day of liver abscess diagnosis. Thus the mortality rate directly related to hepatic abscess was 11.8% (2/17). The duration of hospitalization ranged from 7 to 378 days (mean, 52.5 ± 86.0 days). Discussion In our study, as in the literature, liver abscess formation after transarterial chemoembolization was not rare when underlying p (Univariate) a p (Multivariate) b Odds Ratio 95% CI for Odds Ratio Child-Pugh class B 13/58 (22.4) 4/7 (57.1) Diabetes mellitus 11/42 (26.2) 6/23 (26.1) Leukopenia 11/52 (21.2) 6/13 (46.2) Antibiotics 6/17 (35.3) 11/48 (22.9) Single tumor 8/39 (20.5) 9/26 (34.6) Tumor size 3 cm 12/47 (25.5) 5/18 (27.8) Tumor burden 10% 15/57 (26.3) 2/8 (25.0) Type of tumor (HCC) 8/32 (25.0) 9/33 (27.3) Portal vein thrombosis 17/62 (27.4) 0/3 (0.0) Iodized oil dose c Embolization or portogram (grade 2) 3/36 (8.3) 14/29 (48.3) < Note Numbers in parentheses are percentages. a p for Fisher exact test analyzed for all variables. b p for multivariate linear logistic regression analysis analyzed for variables with p < 0.1 in univariate analysis. c Linear-by-linear association. bilioenteric anastomosis was present. The overall incidence in our series, 17/65 (26.2%) per procedure and 12/25 (48.0%) per patient, was comparable to previous reported values. De Baère et al. [10] reviewed the cases of 561 patients who underwent local treatment of liver tumors. Although the overall rate of liver abscess was 0.7%, liver abscess developed in three of four (75%) patients who underwent bilioenteric anastomosis. In another study, Kim et al. [8] performed 397 TACE procedures and reported an abscess rate of 2.0%. However, the incidence was 6/7 (85.7%) in a subgroup of patients with a history of pancreaticoduodenectomy. Although the study population was small, Ishikawa et al. [19] also reported a high rate (2/3, 66.7%) of liver abscess from TACE after pancreaticoduodenectomy. Song et al. [7], however, reported that only 4 of 55 (7.3%) patients with type 2 biliary abnormality had a liver abscess. However, the definition of type 2 biliary abnormality included not only bilioenteric anastomosis but also other conditions, such as endoscopic papillotomy and percutaneous transhepatic biliary drainage. In this study, we identified several other potential risk factors that correlated with the development of liver abscess. Regarding patient and tumor characteristics, the incidence was significantly higher among patients with leukopenia and those in whom a liver abscess developed at the first session of TACE. With regard to technical aspects of TACE, grade 2 AJR:200, June

7 Woo et al. embolization with absorbable gelatin sponge or grade 2 visualization of oily portogram correlated with a significantly elevated incidence of liver abscess. The higher incidence of liver abscess after grade 2 visualization of an oily portogram may be explained by the fact that grade 2 oily portogram indicates adequate blockage of the portal supply to tumors [18]. This is attributed to the semifluid nature of iodized oil, which allows it to flow into the surrounding portal veins, allowing visualization of the oily portogram via the peribiliary plexus, vasa vasorum of the portal vein, and drainage routes from HCC when TACE is performed in a selective manner [20]. Furthermore, if particulate embolization is performed, additional blockage of arterial supply is expected. It is well known that gelatin particles occlude the artery temporarily, recanalization occurring within 2 weeks [21]. Therefore, when the portal blood supply is obstructed owing to achievement of a grade 2 oily portogram, when arterial flow is blocked owing to particulate embolization, or when both of these conditions are present, massive necrosis of the tumor and atrophy of surrounding hepatic parenchyme can be accomplished within this limited area. In the literature, this is referred to as a subsegmentectomy-like effect [22, 23]. Our results are in agreement with those of a previous study [7] that showed that although not independently significant, embolization with gelatin sponge was associated with an increased incidence of abscess when portal vein obstruction was present. Still, such stronger necrosis alone does not yield a high rate of abscess formation [22]. With an underlying bilioenteric anastomosis, however, in which bile ducts are contaminated by enteric bacteria in a retrograde manner, various disruptions, including TACE with grade 2 particulate embolization or oily portogram visualization, may transform this contamination into obvious infection [19, 24]. In regard to tumor characteristics, there was no statistically significant relation between tumor type and liver abscess formation. In the literature, however, liver abscess has been reported to be more frequent after embolization of metastatic tumors [7, 8, 10]. In our review of the literature, we found that two of three (66.7%), six of seven (85.7%), and three of three (100%) patients in the studies by Song et al. [7], Kim et al. [8], and de Baère et al. [10] with metastasis who had an abscess after TACE had previously undergone bilioenteric anastomosis. We agree with Song et al. [7] that tumor type in itself is not a significant factor in the development of abscess. In our study, the use of prophylactic antibiotics did not significantly decrease the incidence of liver abscess. However, antibiotics were not administered according to a standardized regimen. The antibiotics given usually were a third-generation cephalosporin with or without metronidazole. In the literature, controversy persists over the role of antibiotics in preventing abscess [8, 13 15]. A few studies, however, have shown promising results that vigorous antibiotic prophylaxis may be helpful in preventing liver abscess. Khan et al. [15] observed no development of abscess after TACE in patients with previous biliary interventions when moxifloxacin, an antibiotic with a high degree of biliary secretion, was administered. Geschwind et al. [14] reported that prophylaxis with tazobactampiperacillin and bowel preparation resulted in no abscess formation in patients who underwent bilioenteric anastomosis followed by chemoembolization. In addition, Hoffmann et al. [25] suggested that at least 10 days of antibiotic therapy to cover anaerobic bacteria may be helpful in preventing abscess formation in patients with bilioenteric anastomosis who undergo percutaneous radiofrequency ablation. Therefore, although our results did not show usefulness of routine antibiotic prophylaxis in preventing abscess formation after TACE in patients with bilioenteric anastomosis, we carefully speculate that use of vigorous antibiotic prophylaxis as suggested in more recent literature may be effective. We believe that our study results may assist in establishing a guideline for TACE in patients with a history of bilioenteric anastomosis. In our study, liver abscess developed after approximately 50% of the procedures on patients with risk factors such as leukopenia, liver abscess occurring at first session of TACE, and use of high-risk TACE technique. Therefore, at the initial session of TACE, precaution is required for those with leukopenia, and vigorous prophylactic antibiotic administration should be undertaken in advance. When chemoembolization is performed with high-risk technique (grade 2 particulate embolization or oily portogram), close observation is needed for early detection and timely management with antibiotics and PCD. Furthermore, the patient should be observed for liver abscess formation after the first session of TACE. If abscess formation occurs after TACE with a high-risk technique, additional sessions should be tried with a low-risk technique. If an abscess develops even though TACE is performed without a high-risk technique, the risk of abscess may be considered high in the corresponding patient regardless of TACE technique, and therefore special attention should be paid. The main limitation of our study was the long period of data collection and the corresponding lack of standardization of the methods of chemoembolization and periprocedural care. However, TACE is a technique with a great deal of flexibility that must be tailored to tumor and patient characteristics. Therefore, the heterogeneity was essential for analyzing risk factors for the development of liver abscess. Furthermore, TACE was performed with conventional methods with iodized oil. TACE is currently being performed with more diverse therapeutic agents, such as drug-eluting beads, which have been suggested as being associated with increased risk of liver and biliary injuries. Further studies for comparison of different therapeutic agents with respect to risk of liver abscess are warranted. In addition, this study was retrospective, and there may have been selection bias in how the patients were treated. Moreover, the sample size was relatively small owing to the paucity of patients who underwent bilioenteric anastomosis followed by TACE. Nevertheless, we do not believe statistical power was limited for elucidating several risk factors for liver abscess formation. Conclusion The incidence of liver abscess formation was high among patients with bilioenteric anastomosis who underwent TACE. Leukopenia, occurrence of liver abscess at initial session of TACE, and grade 2 particulate embolization or oily portogram were found to be risk factors for development of liver abscess. Therefore, in patients with such risk factors, TACE should be performed with even more caution than usual, and close follow-up is required for early detection and timely management of liver abscess. References 1. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: Ho AS, Picus J, Darcy MD, et al. Long-term out AJR:200, June 2013

8 Liver Abscess After Transarterial Chemoembolization come after chemoembolization and embolization cinoma. Am J Gastroenterol 1997; 92: tumor recurrence and visualization of the portal of hepatic metastatic lesions from neuroendocrine 12. Vanderwalde AM, Marx H, Leong L. Liver ab- vein with iodized oil. J Vasc Interv Radiol 2007; tumors. AJR 2007; 188: scess as a complication of hepatic transarterial 18: Therasse E, Breittmayer F, Roche A, et al. Trans- chemoembolization: a case report, literature re- 19. Ishikawa O, Ohigashi H, Yasuda T, et al. Transar- catheter chemoembolization of progressive carci- view, and clinical recommendations. Gastrointest terial chemoembolization in metastatic liver tu- noid liver metastasis. Radiology 1993; 189: Cancer Res 2009; 3: mor after curative resection of pancreatic cancer. 5. Sun Z, Li G, Ai X, et al. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol 2011; 79: Chung JW, Park JH, Han JK, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198: Song SY, Chung JW, Han JK, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 2001; 12: Kim W, Clark TW, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12: Xia J, Ren Z, Ye S, et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol 2006; 59: de Baère T, Roche A, Amenabar JM, et al. Liver abscess formation after local treatment of liver tumors. Hepatology 1996; 23: Chen C, Chen PJ, Yang PM, et al. Clinical and microbiological features of liver abscess after transarterial embolization for hepatocellular car- 13. Plentz RR, Lankisch TO, Basturk M, et al. Prospective analysis of German patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization with or without prophylactic antibiotic therapy. J Gastroenterol Hepatol 2005; 20: Geschwind JF, Kaushik S, Ramsey DE, Choti MA, Fishman EK, Kobeiter H. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 2002; 13: Khan W, Sullivan KL, McCann JW, et al. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study. AJR 2011; 197:[web] W343 W Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: Shibata T, Yamamoto Y, Yamamoto N, et al. Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol 2003; 14: Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local Gan To Kagaku Ryoho 1988; 15: Terayama N, Matsui O, Gabata T, et al. Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization. Cardiovasc Intervent Radiol 2001; 24: Coldwell DM, Stokes KR, Yakes WF. Embolotherapy: agents, clinical applications, and techniques. Radiographics 1994; 14: ; quiz Matsui O, Kadoya M, Yoshikawa J, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188: Matsui O, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Demachi H. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 1994; 33(suppl):S84 S Spies JB, Rosen RJ, Lebowitz AS. Antibiotic prophylaxis in vascular and interventional radiology: a rational approach. Radiology 1988; 166: Hoffmann R, Rempp H, Schmidt D, Pereira PL, Claussen CD, Clasen S. Prolonged antibiotic prophylaxis in patients with bilioenteric anastomosis undergoing percutaneous radiofrequency ablation. J Vasc Interv Radiol 2012; 23: AJR:200, June

CHEMOEMBOLISATION USING IODIZED OIL(LIPIODOL ) BASED TECHNIQUES

CHEMOEMBOLISATION USING IODIZED OIL(LIPIODOL ) BASED TECHNIQUES CHEMOEMBOLISATION USING IODIZED OIL(LIPIODOL ) BASED TECHNIQUES Peter Huppert Department of Radiology, Neuroradiology and Nuclear Medicine Klinikum Darmstadt ATH Universities of Frankfurt and Heidelberg/Mannhein

More information

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT

More information

MDCT findings after hepatic chemoembolization with DC-beads: What the radiologist needs to know

MDCT findings after hepatic chemoembolization with DC-beads: What the radiologist needs to know Abdominal Imaging ª Springer Science+Business Media New York 2012 Published online: 10 October 2012 Abdom Imaging (2013) 38:778 784 DOI: 10.1007/s00261-012-9963-6 MDCT findings after hepatic chemoembolization

More information

is based on the fact that HCCs are exclusively supplied by the hepatic artery. When a tumor is advanced in stage

is based on the fact that HCCs are exclusively supplied by the hepatic artery. When a tumor is advanced in stage Hepatocellular Carcinoma with Internal Mammary Artery Supply: Feasibility and Efficacy of Transarterial Chemoembolization and Factors Affecting Patient Prognosis Hyo-Cheol Kim, MD, Jin Wook Chung, MD,

More information

Index terms: Liver, CT Liver neoplasm, CT. Korean J Radiol 2005;6: Received February 21, 2005; accepted after revision May 24, 2005.

Index terms: Liver, CT Liver neoplasm, CT. Korean J Radiol 2005;6: Received February 21, 2005; accepted after revision May 24, 2005. Depiction of Viable Tumor in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: Multiphasic Helical CT with Review of the Previous Serial CT Images Kyung Mi Jang, MD 1 Dongil Choi,

More information

Jin Wook Chung, MD 1 Hyo-Cheol Kim, MD 1 Jung-Hwan Yoon, MD 2 Hyo-Suk Lee, MD 2 Hwan Jun Jae, MD 1 Whal Lee, MD 1 Jae Hyung Park, MD 1

Jin Wook Chung, MD 1 Hyo-Cheol Kim, MD 1 Jung-Hwan Yoon, MD 2 Hyo-Suk Lee, MD 2 Hwan Jun Jae, MD 1 Whal Lee, MD 1 Jae Hyung Park, MD 1 Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma: Prevalence and Causative Factors of Extrahepatic Collateral Arteries in 479 Patients Jin Wook Chung, MD 1 Hyo-Cheol Kim, MD 1 Jung-Hwan

More information

ISCHEMIC COMPLICATIONS OF TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION IN LIVER MALIGNANCIES

ISCHEMIC COMPLICATIONS OF TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION IN LIVER MALIGNANCIES Acta Radiologica 41 (2000) 156 160 Copyright C Acta Radiologica 2000 Printed in Denmark All rights reserved ACTA RADIOLOGICA ISSN 0284-1851 ISCHEMIC COMPLICATIONS OF TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION

More information

Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center

Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer

More information

Multiple Primary Quiz

Multiple Primary Quiz Multiple Primary Quiz Case 1 A 72 year old man was found to have a 12 mm solid lesion in the pancreatic tail by computed tomography carried out during a routine follow up study of this patient with adult

More information

Hepatocellular Carcinomas Smaller Than 4 cm Supplied by the Intercostal Artery: Can We Predict Which Intercostal Artery Supplies the Tumor?

Hepatocellular Carcinomas Smaller Than 4 cm Supplied by the Intercostal Artery: Can We Predict Which Intercostal Artery Supplies the Tumor? Original Article http://dx.doi.org/10.3348/kjr.2011.12.6.693 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2011;12(6):693-699 Hepatocellular Carcinomas Smaller Than 4 cm Supplied by the Intercostal Artery:

More information

Bronchobiliary fistula treated with histoacryl embolization under bronchoscopic guidance: A case report

Bronchobiliary fistula treated with histoacryl embolization under bronchoscopic guidance: A case report Respiratory Medicine CME (2008) 1, 164 168 respiratory MEDICINE CME CASE REPORT Bronchobiliary fistula treated with histoacryl embolization under bronchoscopic guidance: A case report Jung Hyun Kim a,

More information

Transarterial chemoembolization (TACE), which involves

Transarterial chemoembolization (TACE), which involves J Clin Gastroenterol 2001;32(5):423 427. 2001 Lippincott Williams & Wilkins, Inc. Ischemic Bile Duct Injury as a Serious Complication After Transarterial Chemoembolization in Patients with Hepatocellular

More information

Editorial Process: Submission:05/15/2018 Acceptance:11/14/2018

Editorial Process: Submission:05/15/2018 Acceptance:11/14/2018 DOI:10.31557/APJCP.2018.19.12.3545 Predictive Factors after Selective TACE in HCC Patients RESEARCH ARTICLE Editorial Process: Submission:05/15/2018 Acceptance:11/14/2018 Rate and Predictive Factors for

More information

Polyvinyl Alcohol Embolization Adjuvant to Oily Chemoembolization in Advanced Hepatocellular Carcinoma with Arterioportal Shunts

Polyvinyl Alcohol Embolization Adjuvant to Oily Chemoembolization in Advanced Hepatocellular Carcinoma with Arterioportal Shunts Polyvinyl Alcohol Embolization Adjuvant to Oily Chemoembolization in Advanced Hepatocellular Carcinoma with Arterioportal Shunts Yeo Ju Kim, MD 1 Hae Giu Lee, MD 1 Jeong Mi Park, MD 2 Yeon Soo Lim, MD

More information

Post-operative complications following hepatobiliary surgery: imaging findings and current radiological treatment options

Post-operative complications following hepatobiliary surgery: imaging findings and current radiological treatment options Post-operative complications following hepatobiliary surgery: imaging findings and current radiological treatment options Poster No.: C-1501 Congress: ECR 2015 Type: Educational Exhibit Authors: A. Hadjivassiliou,

More information

Staging & Current treatment of HCC

Staging & Current treatment of HCC Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt

More information

Early Infectious Complications of Percutaneous Metallic Stent Insertion for Malignant Biliary Obstruction

Early Infectious Complications of Percutaneous Metallic Stent Insertion for Malignant Biliary Obstruction Vascular and Interventional Radiology Original Research Sol et al. Stent Insertion in Biliary Obstruction Vascular and Interventional Radiology Original Research Yu Li Sol 1 Chang Won Kim 1 Ung Bae Jeon

More information

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which

More information

Phase II Study of Chemoembolization with Drug-eluting Beads in Patients with Hepatic. Neuroendocrine Metastases: Interim Analysis

Phase II Study of Chemoembolization with Drug-eluting Beads in Patients with Hepatic. Neuroendocrine Metastases: Interim Analysis Phase II Study of Chemoembolization with Drug-eluting Beads in Patients with Hepatic Neuroendocrine Metastases: Interim Analysis Original research Advances in knowledge: 1. The incidence of biloma and

More information

Locoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates

Locoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses

More information

Hepatocellular Carcinoma: Diagnosis and Management

Hepatocellular Carcinoma: Diagnosis and Management Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm

More information

Transarterial Chemoembolization in Neuroendocrine Liver Metastasis

Transarterial Chemoembolization in Neuroendocrine Liver Metastasis Transarterial Chemoembolization in Neuroendocrine Liver Metastasis Ricardo D. Garcia-Monaco, MD, PhD, FSIR; Andres Alejandro Kohan, MD From Vascular and Interventional Radiology, Department of Radiology,

More information

Long-term follow-up after conventional transarterial chemoembolization (c-tace) with mitomycin for hepatocellular carcinoma (HCC)

Long-term follow-up after conventional transarterial chemoembolization (c-tace) with mitomycin for hepatocellular carcinoma (HCC) Original Article Long-term follow-up after conventional transarterial chemoembolization (c-tace) with mitomycin for hepatocellular carcinoma (HCC) Ricardo Yamada, Beatriz Bassaco, Stephen Bracewell, Kirkpatrick

More information

ULTRA FLUID. Lipiodol efficacy & safety. for improved overall survival in HCC. Localization. Vectorization. Visualization. Chemo-Embolization

ULTRA FLUID. Lipiodol efficacy & safety. for improved overall survival in HCC. Localization. Vectorization. Visualization. Chemo-Embolization Ethyl ester of iodized fatty acids of poppy seed oil ULTRA FLUID Lipiodol efficacy & safety 1,2,3,4 for improved overall survival in HCC Localization Endorsed by International HCC Treatment Guidelines

More information

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer

More information

Does Establishing a Safety Margin Reduce Local Recurrence in Subsegmental Transarterial Chemoembolization for Small Nodular Hepatocellular Carcinomas?

Does Establishing a Safety Margin Reduce Local Recurrence in Subsegmental Transarterial Chemoembolization for Small Nodular Hepatocellular Carcinomas? Original Article Intervention http://dx.doi.org/10.3348/kjr.2015.16.5.1068 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2015;16(5):1068-1078 Does Establishing a Safety Margin Reduce Local Recurrence

More information

Lin Yang, Xiao Ming Zhang, Yong Jun Ren, Nan Dong Miao, Xiao Hua Huang, and Guo Li Dong

Lin Yang, Xiao Ming Zhang, Yong Jun Ren, Nan Dong Miao, Xiao Hua Huang, and Guo Li Dong Radiology Research and Practice Volume 2013, Article ID 535272, 6 pages http://dx.doi.org/10.1155/2013/535272 Clinical Study The Features of Extrahepatic Collateral Arteries Related to Hepatic Artery Occlusion

More information

A Metastatic Adrenal Tumor from a Hepatocellular Carcinoma: Combination Therapy with Transarterial

A Metastatic Adrenal Tumor from a Hepatocellular Carcinoma: Combination Therapy with Transarterial A Metastatic Adrenal Tumor from a Hepatocellular Carcinoma: Combination Therapy with Transarterial Chemoembolization and Radiofrequency Ablation 1 Hyun-Jin Lim, M.D., Yun Ku Cho, M.D., Yong-Sik Ahn, M.D.,

More information

Hepatocellular Carcinoma Rupture after Transcatheter Arterial Chemoembolization

Hepatocellular Carcinoma Rupture after Transcatheter Arterial Chemoembolization Chin J Radiol 2004; 29: 41-45 41 Hepatocellular Carcinoma Rupture after Transcatheter Arterial Chemoembolization KUNG-SHIH YING 1 SHYUH-HUEI HUANG 2 CHE-JEN CHAO 3 SHIN-HWA WU 1 TAI-YU CHANG 1 CHUNG-HSEIN

More information

Intra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization

Intra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization Intra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization Department of Radiology, National Cancer Center In Joon Lee Contents Conventional TACE Role of TACE in management

More information

Embolotherapy for Cholangiocarcinoma: 2016 Update

Embolotherapy for Cholangiocarcinoma: 2016 Update Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial

More information

General summary GENERAL SUMMARY

General summary GENERAL SUMMARY General summary GENERAL SUMMARY In Chapter 2.1 the long-term results and prognostic factors of radiofrequency ablation (RFA) for unresectable colorectal liver metastases (CRLM) in a single center with

More information

A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma

A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma pissn 2287-2728 eissn 2287-285X Case Report Clinical and Molecular Hepatology 2012;18:321-325 A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with

More information

Ruolo della interventistica per le secondarietà epatiche e di altre sedi

Ruolo della interventistica per le secondarietà epatiche e di altre sedi Ruolo della interventistica per le secondarietà epatiche e di altre sedi Giancarlo Bizzarri Dipartimento di Diagnostica per Immagini e Radiologia Interventistica Ospedale Regina Apostolorum, Albano Laziale

More information

transcatheter arterial chemoembolization,

transcatheter arterial chemoembolization, Embolization Efficacy and Treatment Effectiveness of Transarterial Therapy for Unresectable Hepatocellular Carcinoma: A Case-Controlled Comparison of Transarterial Ethanol Ablation with Lipiodol Ethanol

More information

Tumor Response to Transcatheter Arterial Chemoembolization in Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation

Tumor Response to Transcatheter Arterial Chemoembolization in Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation Tumor Response to Transcatheter Arterial Chemoembolization in Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation Heung-Kyu Ko, MD 1 Gi-Young Ko, MD 2 Hyun Ki Yoon, MD 2 Kyu-Bo

More information

Interventional Radiologic Treatment of Hepatocellular Carcinoma

Interventional Radiologic Treatment of Hepatocellular Carcinoma Interventional Radiologic Treatment of Hepatocellular Carcinoma Fatih Boyvat Abstract The current treatment modalities for patients with hepatocellular carcinoma are discussed in this review. Hepatocellular

More information

PEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good

PEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good Reviewer s code: 03656588 Reviewer s country: China Date reviewed: 2017-06-08 [ ] Grade A: Excellent [ Y] Accept [ ] Grade B: Very good [ ] High priority for [ Y] Grade C: Good language [ ] Major revision

More information

RADIATION SEGMENTECTOMY. Robert J Lewandowski, MD

RADIATION SEGMENTECTOMY. Robert J Lewandowski, MD RADIATION SEGMENTECTOMY Robert J Lewandowski, MD Robert Lewandowski, M.D. Consultant/Advisory Board: Cook Medical, LLC, Arsenal, BTG International, Boston Scientific Corp., ABK Reference Unlabeled/Unapproved

More information

Current Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005

Current Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005 Current Treatment of Colorectal Metastases Dr. Thavanathan Surgical Grand Rounds February 1, 2005 25% will have metastases at initial presentation 25-50% 50% will develop metastases later 40% of potentially

More information

Treatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center

Treatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

Feasibility Study of Transcatheter Arterial Chemoembolization with Epirubicin Drug-eluting Beads for Hepatocellular Carcinoma in Japanese Patients

Feasibility Study of Transcatheter Arterial Chemoembolization with Epirubicin Drug-eluting Beads for Hepatocellular Carcinoma in Japanese Patients Original Research Feasibility Study of Transcatheter Arterial Chemoembolization with Epirubicin Drug-eluting Beads for Hepatocellular Carcinoma in Japanese Patients 1) Department of Diagnostic Radiology,

More information

Bacterial Infections Associated with Hepatic Arteriography and Transarterial Embolization for Hepatocellular Carcinoma: A Prospective Study

Bacterial Infections Associated with Hepatic Arteriography and Transarterial Embolization for Hepatocellular Carcinoma: A Prospective Study 161 Bacterial Infections Associated with Hepatic Arteriography and Transarterial Embolization for Hepatocellular Carcinoma: A Prospective Study Chiher Chen, Yuk-Ming Tsang, Po-Ren Hsueh, Guan-Tarn Huang,

More information

Early Klebsiella pneumoniae Liver Abscesses associated with Pylephlebitis Mimic

Early Klebsiella pneumoniae Liver Abscesses associated with Pylephlebitis Mimic Early Klebsiella pneumoniae Liver Abscesses associated with Pylephlebitis Mimic Hepatocellular Carcinoma Chih-Hao Shen, MD 3, Jung-Chung Lin, MD, PhD 2, Hsuan-Hwai Lin, MD 1, You-Chen Chao, MD 1, and Tsai-Yuan

More information

100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days

100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days 100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,

More information

Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies

Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Policy Number: 8.01.11 Last Review: 6/2018 Origination: 8/2005 Next Review: 6/2019 Policy Blue Cross and Blue

More information

Case Report pissn J Korean Soc Radiol 2012;67(4): INTRODUCTION CASE REPORT

Case Report pissn J Korean Soc Radiol 2012;67(4): INTRODUCTION CASE REPORT Case Report pissn 1738-2637 Focal Fat Deposition Developed in the Segment IV of the Liver Following Gastrectomy Mimicking a Hepatic Metastasis: Two Case Reports 1 위절제술후에간의제 4 분절에서발생한간전이를닮은국소지방침윤 : 두증례보고

More information

Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging

Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery

More information

Liver Cancer: Diagnosis and Treatment Options

Liver Cancer: Diagnosis and Treatment Options Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver

More information

WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?

WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views

More information

The Egyptian Journal of Hospital Medicine (April 2018) Vol. 71(1), Page

The Egyptian Journal of Hospital Medicine (April 2018) Vol. 71(1), Page The Egyptian Journal of Hospital Medicine (April 2018) Vol. 71(1), Page 2315-2321 Role of MRI in Assessment of Hepatocellular Carcinoma (HCC) after TACE (Trans-arterial Chemoembolization) with Persistent

More information

Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?

Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:

More information

Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma After Attempted Portal Vein Embolization in 25 Patients

Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma After Attempted Portal Vein Embolization in 25 Patients Vascular and Interventional Radiology Clinical Observations Kang et al. TCE for HCC fter Portal Vein Embolization Vascular and Interventional Radiology Clinical Observations o-kyeong Kang 1 Jin Hyoung

More information

Chemoembolization of Hepatocellular Carcinoma

Chemoembolization of Hepatocellular Carcinoma 3 Chemoembolization of Hepatocellular Carcinoma RiccardoLencioni,MD,FSIR,EBIR 1 Pasquale Petruzzi, MD 1 LauraCrocetti,MD,PhD,EBIR 1 1 Division of Diagnostic Imaging and Intervention, Pisa University School

More information

Vascular Complications of Hepatic Artery After Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinoma

Vascular Complications of Hepatic Artery After Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinoma Vascular and Interventional Radiology Pictorial Essay Sueyoshi et al. TE in Hepatocellular arcinoma Downloaded from www.ajronline.org by 37.44.199.42 on 02/04/18 from IP address 37.44.199.42. opyright

More information

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer

More information

SIR- RFS Journal Primer

SIR- RFS Journal Primer Comparison of Combina-on Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoemboliza-on with Radiofrequency Abla-on versus Microwave Abla-on SIR- RFS Journal Primer Quick Summary

More information

Management of Colorectal Liver Metastases

Management of Colorectal Liver Metastases Management of Colorectal Liver Metastases MM Bernon, JEJ Krige HPB Surgical Unit, Groote Schuur Hospital Department of Surgery, University of Cape Town 50% of patients with colorectal cancer develop liver

More information

MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC

MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY

More information

Surgical Management of Pancreatic Cancer

Surgical Management of Pancreatic Cancer I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated

More information

CT Findings of Afferent Loop Varices After Bilioenteric Anastomosis in Patients With Malignant Disease

CT Findings of Afferent Loop Varices After Bilioenteric Anastomosis in Patients With Malignant Disease Gastrointestinal Imaging Original Research Lee et al. CT Findings of Afferent Loop Varices Gastrointestinal Imaging Original Research Dong Ho Lee 1 Young Hoon Kim 2 Yoon Jin Lee 2 Kyoung Ho Lee 2 So Yeon

More information

Liver Perfusion Analysis New Frontiers in Dynamic Volume Imaging. Case Study Brochure Chang Gung Memorial Hospital.

Liver Perfusion Analysis New Frontiers in Dynamic Volume Imaging. Case Study Brochure Chang Gung Memorial Hospital. New Frontiers in Dynamic Volume Imaging dynamic volume CT Case Study Brochure Chang Gung Memorial Hospital http://www.toshibamedicalsystems.com Toshiba Medical Systems Corporation 2010-2011. All rights

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Cryosurgical Ablation of Primary or Metastatic Liver Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: cryosurgical_ablation_of_primary_or_metastatic_liver_tumors

More information

Percutaneous Transhepatic Stent Placement in the Management of Portal Venous Stenosis After Curative Surgery for Pancreatic and Biliary Neoplasms

Percutaneous Transhepatic Stent Placement in the Management of Portal Venous Stenosis After Curative Surgery for Pancreatic and Biliary Neoplasms Vascular and Interventional Radiology Original Research Kim et al. Transhepatic Stent Placement for Postsurgical Stenosis Vascular and Interventional Radiology Original Research Kyung Rae Kim 1 Gi-Young

More information

DEB-TACE vs Conventional TACE in Intermediate HCC: Best Candidates for DEB-TACE?

DEB-TACE vs Conventional TACE in Intermediate HCC: Best Candidates for DEB-TACE? DEB-TACE vs Conventional TACE in Intermediate HCC: Best Candidates for DEB-TACE? Ho Jong Chun, MD., PhD Seoul St. Mary s Hospital, The Catholic University of Korea Why Drug-eluting Beads? Clear Rationale

More information

HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)

HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,

More information

Locoregional Therapy for Hepatoma

Locoregional Therapy for Hepatoma Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish

More information

pitfall Table 1 4 disorientation pitfall pitfall Table 1 Tel:

pitfall Table 1 4 disorientation pitfall pitfall Table 1 Tel: 11 687 692 2002 pitfall 1078 29 17 9 1 2 3 dislocation outflow block 11 1 2 3 9 1 2 3 4 disorientation pitfall 11 687 692 2002 Tel: 075-751-3606 606-8507 54 2001 8 27 2002 10 31 29 4 pitfall 16 1078 Table

More information

The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma

The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma Sung Wook Shin, MD Index terms: Carcinoma, hepatocellular Chemoembolization, therapeutic Iodized oil

More information

Unmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim

Unmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC

More information

Regional Therapy for Metastatic Neuroendocrine Tumors. Janette Durham, MD Professor of Radiology University of Colorado School of Medicine

Regional Therapy for Metastatic Neuroendocrine Tumors. Janette Durham, MD Professor of Radiology University of Colorado School of Medicine Regional Therapy for Metastatic Neuroendocrine Tumors Janette Durham, MD Professor of Radiology University of Colorado School of Medicine Introduce regional therapy for mnet Arterial therapies Injection

More information

Si Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong Jun Song, 1,4 Woo Jin Chung, 1,5

Si Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong Jun Song, 1,4 Woo Jin Chung, 1,5 Comparison of efficacy between hepatic arterial infusion chemotherapy and sorafenib in advanced hepatocellular carcinoma with portal vein tumor thrombosis 1,2,3 Si Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong

More information

doi: /hepr Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)

doi: /hepr Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version) bs_bs_banner Hepatology Research 2016; 46: 3 9 doi: 10.1111/hepr.12542 Special Report Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version) Masatoshi Kudo, Kazuomi Ueshima,

More information

Liver Tumors. Patient Education. Treatment options 8 4A. About the Liver. Surgical Specialties

Liver Tumors. Patient Education. Treatment options 8 4A. About the Liver. Surgical Specialties Patient Education Treatment options This handout describes different kinds of tumors that form in the liver and how they are treated. About the Liver Your liver is the largest organ in your abdomen. It

More information

Gut Online First, published on May 5, 2005 as /gut

Gut Online First, published on May 5, 2005 as /gut Gut Online First, published on May 5, 2005 as 10.1136/gut.2005.069237 p53 gene (Gendicine ) and embolization overcame recurrent hepatocellular carcinoma Guan YS, Liu Y, Zhou XP, Li X, He Q, Sun L. Authors

More information

Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines

Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in

More information

Preoperative Biliary Drainage Among Patients With Resectable Hepatobiliary Malignancy: Does Technique Matter?

Preoperative Biliary Drainage Among Patients With Resectable Hepatobiliary Malignancy: Does Technique Matter? Preoperative Biliary Drainage Among Patients With Resectable Hepatobiliary Malignancy: Does Technique Matter? Q. Lina Hu, MD; Jason B. Liu, MD, MS; Ryan J. Ellis, MD, MS; Jessica Y. Liu, MD, MS; Anthony

More information

Superselective vs. lobar transarterial ethiodized oil-chemoembolization - occurrence and clinical significance of non-target embolization

Superselective vs. lobar transarterial ethiodized oil-chemoembolization - occurrence and clinical significance of non-target embolization Superselective vs. lobar transarterial ethiodized oil-chemoembolization - occurrence, p. 13-22 Interventional HR J Original Article Superselective vs. lobar transarterial ethiodized oil-chemoembolization

More information

To evaluate 792 patients with malignant biliary obstruction after inner-stents drainage procedure

To evaluate 792 patients with malignant biliary obstruction after inner-stents drainage procedure To evaluate 792 patients with malignant biliary obstruction after inner-stents drainage procedure Zhu wei, Zhang xiquan, Pan xiaolin, Dong ge, Guo feng. The Cardio-Interventional Center, The 148th PLA

More information

80 Cancer Control. Special Report

80 Cancer Control. Special Report Special Report Cancer Control Journal of the Moffitt Cancer Center Transcatheter Arterial Chemoembolization and Percutaneous Ethanol Injection for Hepatocellular Carcinoma: A Retrospective Review of the

More information

Analysis of efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma

Analysis of efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma JBUON 2019; 24(1): 163-170 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Analysis of efficacy and safety of TACE in combination with RFA and

More information

Afferent Loop Syndrome: Treatment by Means of the Placement of Dual Stents

Afferent Loop Syndrome: Treatment by Means of the Placement of Dual Stents Vascular and Interventional Radiology Original Research Han et al. Use of Dual Stents for Treatment of Afferent Loop Syndrome Vascular and Interventional Radiology Original Research Kichang Han 1 Ho-Young

More information

Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions

Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions DOI:http://dx.doi.org/10.7314/APJCP.2016.17.2.473 Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions MINI-REVIEW Transarterial Therapies

More information

6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration

6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration

More information

INTRAARTERIAL TREATMENT OF COLORECTAL LIVER METASTASES. Dr. Joan Falcó Interventional Radiology UDIAT. Hospital Universitari Parc Taulí

INTRAARTERIAL TREATMENT OF COLORECTAL LIVER METASTASES. Dr. Joan Falcó Interventional Radiology UDIAT. Hospital Universitari Parc Taulí INTRAARTERIAL TREATMENT OF COLORECTAL LIVER METASTASES Dr. Joan Falcó Interventional Radiology UDIAT. Hospital Universitari Parc Taulí STRATEGIES FOR CRLM LIVER METASTASES Extended indications Resectable

More information

Individualized laparoscopic B-ultrasound-guided microwave ablation for multifocal primary liver cancer

Individualized laparoscopic B-ultrasound-guided microwave ablation for multifocal primary liver cancer Original paper General surgery Videosurgery Individualized laparoscopic B-ultrasound-guided microwave ablation for multifocal primary liver cancer Zhifeng Xu, Zhangwei Yang, Jianghua Pan, Yiren Hu Department

More information

Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging

Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging Saturday, November 5, 2005 8:30-10:30 a. m. Poorly Differentiated Endocrine Carcinomas Chairman: E. Van Cutsem, Leuven, Belgium 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders:

More information

Left Inferior Phrenic Artery Feeding Hepatocellular Carcinoma: Angiographic Anatomy Using C-Arm CT

Left Inferior Phrenic Artery Feeding Hepatocellular Carcinoma: Angiographic Anatomy Using C-Arm CT Vascular and Interventional Radiology Clinical Observations Kim et al. Left Inferior Phrenic rtery natomy Using C-rm CT Vascular and Interventional Radiology Clinical Observations FOCUS ON: Hyo-Cheol Kim

More information

Staging and treatment of hepatocellular carcinoma

Staging and treatment of hepatocellular carcinoma Multimodal Image-Guided Tailored Therapy of Early and Intermediate Hepatocellular Carcinoma: Long-Term Survival in the Experience of a Single Radiologic Referral Center Tito Livraghi, 1 Franca Meloni,

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

treatment options for primary liver malignancies and metastatic disease

treatment options for primary liver malignancies and metastatic disease State of the art treatment options for primary liver malignancies and metastatic disease Peter Huppert Prof. of Radiology and Neuroradiology Klinikum Darmstadt Certified Vascular and Oncologic Center Disclosure

More information

Hepatocellular carcinoma: Intra-arterial treatments

Hepatocellular carcinoma: Intra-arterial treatments Hepatocellular carcinoma: Intra-arterial treatments Irene Bargellini U.O. Radiologia Interventistica Azienda Ospedaliero Universitaria Pisana IRENE BARGELLINI,MD UO RADIOLOGIA INTERVENTISTICA, AZIENDA

More information

Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma

Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis

More information

Study Objective and Design

Study Objective and Design Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular

More information

Cholangiocarcinoma (Bile Duct Cancer)

Cholangiocarcinoma (Bile Duct Cancer) Cholangiocarcinoma (Bile Duct Cancer) The Bile Duct System (Biliary Tract) A network of bile ducts (tubes) connects the liver and the gallbladder to the small intestine. This network begins in the liver

More information

Personal Profile. Name: 劉 XX Gender: Female Age: 53-y/o Past history. Hepatitis B carrier

Personal Profile. Name: 劉 XX Gender: Female Age: 53-y/o Past history. Hepatitis B carrier Personal Profile Name: 劉 XX Gender: Female Age: 53-y/o Past history Hepatitis B carrier Chief complaint Fever on and off for 2 days Present illness 94.10.14 Sudden onset of epigastric pain 94.10.15 Fever

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes

More information

5/17/2013. Pancreatic Cancer. Postgraduate Course in General Surgery CASE 1: CASE 1: Overview. Case presentation. Differential diagnosis

5/17/2013. Pancreatic Cancer. Postgraduate Course in General Surgery CASE 1: CASE 1: Overview. Case presentation. Differential diagnosis Overview Case presentation Postgraduate Course in General Surgery Differential diagnosis Diagnosis and therapy Eric K. Nakakura Koloa, HI March 26, 2013 Outcomes CASE 1: CASE 1: A 78-year-old man developed

More information

Intraductal papillary mucinous neoplasm of the bile ducts: a rare form of premalignant lesion of invasive cholangiocarcinoma

Intraductal papillary mucinous neoplasm of the bile ducts: a rare form of premalignant lesion of invasive cholangiocarcinoma Intraductal papillary mucinous neoplasm of the bile ducts: a rare form of premalignant lesion of invasive cholangiocarcinoma Authors: R. Revert Espí, Y. Fernandez Nuñez, I. Carbonell, D. P. Gómez valencia,

More information